Byetta scores new use in the U.S.; Sun rises on proposed Taro plan;

@FiercePharma: DHL, pharma group assess India's hobbled logistics. Report | Follow @FiercePharma

> The FDA has approved a new use for Amylin Pharmaceuticals ($AMLN) and Eli Lilly's ($LLY) Byetta. It is now approved as an add-on therapy to insulin glargine--with or without metformin and/or a thiazolidinedione--in conjunction with diet and exercise for adults with Type 2 diabetes who are not achieving adequate glycemic control on insulin glargine alone. Amylin/Lilly release

> India's Sun Pharma stock rose after the generic drugmaker offered to acquire 100% in the Israeli drug-firm Taro Pharma. The company already has a 66% stake in Taro. But not all of Taro's large shareholders may be eager to go along with Sun's plans. Story

> The SEC is reportedly investigating SAC Capital Investors to determine whether it profited from inside information on Johnson & Johnson's ($JNJ) takeover of Cougar Biotechnology. Article

> Men whose erectile dysfunction is caused by clogged arteries leading to the penis and who don't respond to meds such as Pfizer's ($PFE) Viagra, Bayer's Levitra and Eli Lilly's ($LLY) Cialis may be helped by a Medtronic drug-coated stent, study data revealed. News

> The FDA has extended the initial PDUFA date for its review of the sBLA for Biogen Idec ($BIIB) and Elan's ($ELN) Tysabri. The app was submitted in December 2010 to update the prescribing information for the drug to include anti-JC virus antibody status as a factor to help stratify the risk of progressive multifocal leukoencephalopathy. The agency has indicated that the extension of the PDUFA date is needed to allow time for review of the changes being incorporated into the risk evaluation and mitigation strategies program for the drug. Biogen Idec/Elan release

> Ireland's Immdal Limited has sold its subsidiary Newport Pharmaceuticals Limited to Swiss pharmaceutical company Ewopharma. Immdal release

Biotech News

 @FierceBiotech: Amgen will axe 380 R&D staffers as it trims rising costs. Item | Follow @FierceBiotech

 @JohnCFierce: Thanks to Peter Mueller, Doug Williams, Omid Farokhzad, Tom Hughes and Stephen Knight for an interesting conversation on early stage R&D. | Follow @JohnCFierce

> Will Abbott spinoff become Big Pharma's next big M&A target? Item

> Amgen will axe 380 R&D staffers as it trims rising costs. Story 

Vaccines News

> GSK malaria vaccine works in major Phase III trial. News

> Study: 40% of cancers stem from viruses. Article

> Hoopika lands $10M for vaccine platform. Story

>  Drug has unexpected promise as HIV vaccine. Report

> Twitter opinions linked to vaccine uptake. Item

Manufacturing News

> Rogue online pharmacies try Twitter marketing. Report 

> APP taps parent Fresenius' facilities to boost propofol supply. News 

> GSK warned over lack of contamination control. Article 

> Prevention efforts yield 33% drop in cargo theft. Story

> Hospira plant remediation stings company financials. Piece

> Ben Venue inspection yields 48 GMP violations. Item 

And Finally...  A Kansas doctor and a researcher have admitted to conspiring to defraud Schering-Plough, now a unit of Merck, by falsifying data in a clinical trial. Wayne Spencer and Lisa Sharp each also pleaded guilty to a count of failing to maintain records in a clinical trial, per FDA rules. The judge in the case could order the duo to serve up to 5 years in prison for the conspiracy charge and fine them up to $250,000 each at their sentencing. But, as part of their plea deals, prosecutors agreed to recommend they serve only probation. Story